Characterization and clinical validation of MCM2 and TOP2A monoclonal antibodies in the BD ProEx™ C assay: An immunoassay which detects aberrant S-phase induction in cervical tissue.

Eric P Dixon,Lorraine M King,Ramona Nelson,Stephen G Simkins,Steven L Knapp,George H Brough,Karen L Lenz,Dorian T Henderson,Clark M Whitehead, Janice Hessling,Charlotte A Brown,Douglas P Malinowski

Journal of Immunological Methods（2017）

Cited 9|Views12

No score

Abstract

BD ProEx™ C containing MCM2 and TOP2A antibodies showed strong specific nuclear staining that correlated with increased dysplasia and lesion severity. Enhanced performance of the antibodies was linked to their unique topography recognition. BD ProEx™ C incorporates antibodies that enhance detection of CIN2+ cervical disease.

Translated text

Key words

ProEx™ C,MCM2,TOP2A,SurePath™ liquid-based cytology

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined